Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2012558-47-1
Molecular formula
C248H355N65O72
Molecular weight
5399 g/mol
Drug class
Hepatitis D virus (HDV) entry inhibitormyristoylated pre-S1 lipopeptide
Mechanism of action
Binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, blocking entry of hepatitis B and D viruses into liver cells. It prevents new infection of hepatocytes but does not directly eliminate intracellular viral genomes.
Indications / reported uses
Treatment of chronic hepatitis D virus (HDV) infection in adults with compensated liver disease, with or without concomitant HBV infection, under the EU-authorised Hepcludex indication; use in combination with HBV management as directed by specialist product information
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Bulevirtide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bulevirtide Permitted Daily Exposure (PDE) report (the Bulevirtide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bulevirtide Occupational Exposure Limit (OEL) report (the Bulevirtide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.